An observational study in Breast Cancer, Melanoma and Gastrointestinal Neuroendocrine Tumor, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by University Health Network, Toronto · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies in Breast Neoplasms by University Health Network, Toronto — 18 open to participants now, 22 under way, 1 of them phase 3. Breast Neoplasms · University Health Network, Toronto.
Among the 66 studies in Breast Neoplasms by University Health Network, Toronto, this one is the 5th largest by planned enrollment of the 25 observational ones that give a count, is one of 4 that started in 2022, is one of 25 observational ones, reaches primary completion later than 16 of the 21 other live ones, and was the 53rd registered.
14,832 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →18 of the 66 studies in Breast Neoplasms by University Health Network, Toronto are open now, in 10 countries. Recruiting first, the newest first:
University Health Network, Toronto · Sites in Canada
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18–80
University Health Network, Toronto · Sites in Canada
Ages 18–40
University Health Network, Toronto · Sites in Canada
Ages 18+
By country, each count listing its studies:
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 9 · Phase 3 4
First in 1988; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 800 is above the median of 184 across 3,235 observational studies indexed under Breast Neoplasms.
Median enrollment 100 across the 39 interventional studies, 180 across the 25 observational. Of the 41 that completed or were terminated, 3 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Health Network, Toronto is the lead sponsor of 1,438 studies on the registry; 295 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.
7 of the studies in Breast Neoplasms by University Health Network, Toronto that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02732860University Health Network, TorontoPersonalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host | 2027-01-04 |
| NCT05592938University Health Network, TorontoPartial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE) | 2027-06-27 |
| NCT06085274University Health Network, TorontoSentinel lympH Node Biopsy With Indocyanine Green in Breast Cancer After NEoadjuvant Chemotherapy (SHINE) | 2027-07 |
| NCT05388149University Health Network, TorontoKadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease | 2027-07 |
| NCT01505400University Health Network, TorontoIntegrated Molecular Profiling in Advanced Cancers Trial | 2027-07 |
Add all 7 to your calendar (.ics) → With an account.
Among the 66 studies in Breast Neoplasms by University Health Network, Toronto, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular residual disease (MRD) before metastases become radiographically or clinically detectable. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types.
The development of anticancer drugs typically starts with patients with advanced cancers who have exhausted standard treatments. Yet even the most active new drugs produce only modest benefits in patients with advanced cancers because of the emergence of resistance, similar to the resistance that bacteria develop when they are repeatedly exposed to antibiotics. In order to achieve larger magnitude gains in survival and make greater impact in the field of cancer, promising drugs must be tested in patients with curable malignancies who have undergone definitive treatment but are at high risk of relapse. Interception is the active intervention of cancers at an early stage, offering an opportunity to eliminate molecular residual disease (MRD) before clinical relapse. MRD describes the situation in which cancer-derived biomarkers are detectable, typically using highly sensitive and specific molecular assays in blood or other body substances that are below the threshold of detection by conventional tests such as CT scans or radiological imaging. Using innovative technologies to monitor patients at high risk of relapse, and applying them to serial samples of their circulating tumor DNA, other body fluids, stool and radiological images, the goal is to develop AI-based models to identify those who are at the highest risk of relapse. This will allow interception studies to be conducted to target microscopic tumor cells in these patients to increase cancer cure rates.
Early stage or locally advanced disease that is planned for or have undergone curative treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
None
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with early stage or locally advanced disease that is planned for or have undergone curative treatment will have next-generation sequencing (NGS)-based ctDNA analysis performed on blood samples to determine minimal residual disease (MRD). Blood samples, stool samples, and additional archival/fresh tumor specimens will be collected for banking and future research purposes.
Change from Baseline in ctDNA collected from biospecimens
Next-generation sequencing based ctDNA analysis
Time frame: Through study completion, an average of 4 years
Number of participants that are identified as high risk of clinical relapse with artificial intelligence (AI) and machine learning algorithms
Time frame: Through study completion, an average of 4 years
Plan to share: Undecided — De-identified study data (including genetic data) may be potentially shared with approved research collaborators.
No publications or documents are linked to this record.
Started Jul 2022 (actual). Primary completion is estimated for Jun 2028, 71 months after the start.
Of 1,192 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 138. This study's planned 71 months is above that.
Counting every sponsor, half of 1,381 studies reached it within 55 months; a quarter within 25 and three quarters within 125.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Jun 2027 → Jun 2028 and completion Jun 2027 → Jun 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Health Network, Toronto →